Abstract
The aim of this study was to compare the efficiency of various methods of treating patients with abdominal obesity and dyslipidemia at the stage ofpreclinical manifestation of cardiovascular complications. One group (13 pts) was treated by diets, the other (19 pts) by diet and metmorphine in a daily dose of 1000 mg. The duration of study was 6 months. Anthropometric, biochemical, and hormonal values were checked up in all patients at the beginning and end of therapy and in some patients after 3 months of treatment. The results indicate that metmorphine in combination with traditional therapy is a rational treatment affecting various factors determining the summary risk of cardiovascular diseases in patients with abdominal obesity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
